Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SOPHIA

Financiado

Cerrado

Stratification of Obesity Phenotypes to Optimize Future Therapy

SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of self-control, rather than a disease. We will change this perspective by defining subpopulatio... ver más

31/05/2025

NUID UCD

17M€

Presupuesto del proyecto: 17M€

Líder del proyecto

UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 37 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-26

IMI2-2019-17-01: Optimising future obesity treatment Specific Challenge:The prevalence of obesity is increasing and affects more than 650 million people...

I+D

Cerrada

0% 49% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

37 Participantes

NUID UCD

1.59M€ | Lider

Eli Lilly

750.00K€ | Participante

METABOLON GMBH

464.13K€ | Participante

UCC

20.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2020-05-26
Fecha Fin: 2025-05-31

Líder del proyecto

UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 17M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of self-control, rather than a disease. We will change this perspective by defining subpopulations in terms of (a) the risks of complications linked to obesity, (b) response to various obesity treatments. The subpopulations will be characterised in terms of operational variables (phenotypic, genetic, behavioural, environmental, and omics). These predictive variables will facilitate diagnosis and underpin personalised and protocolised obesity care. Patient priorities regarding risk and response will influence all aspects of our work. SOPHIA will create a federated database of premier EU cohorts to identify operational variables that are predictive of risk and treatment response in people with and without diabetes. We will validate the predictive value of these variables before creating clinically-useful algorithms to decide when-to-treat and how-to-treat. Biomarker variables will feed into innovative assays, tests and research targets. We will interpret and analyse our results, to identify shared value across all stakeholders (patients, clinicians, industry, payers). SOPHIA will change attitudes and experience of obesity by (1) demonstrating the heterogeneity of the disease, (2) identifying people at risk of complications, (3) identifying the best treatment for each individual, (4) delivering a common vocabulary and shared understanding of obesity, (5) demonstrating shared value, which combines commercial opportunity with societal benefit. Our ambition will only be realised if (a) payers agree to fund treatment, (b) industry generate effective treatments, (c) clinicians are prepared to prescribe treatments, and (d) patients are prepared to take treatments. The evidence base does not currently exist. SOPHIA will deliver this evidence and the shared value analysis to drive this revolution in obesity care.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores